Bioheart

Bioheart, which is focused on development therapies for chonic and acute heart damage, went public at $5.25 per share but currently trades at just over $2 per share.

US Market Commentary from Seeking Alpha Renaissance Capital IPO Research 2009

Bioheart focuses on developing treatments for chronic and acute heart damage using patients 'own stem cells to regenerate damaged muscle.

Bioheart Goes Public With a Modest Offering 2008

Bioheart is focused on completing the Phase II/III MARVEL study for chronic heart failure using MyoCell.

unknown title 2011

Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.

unknown title 2011

Lytel, CFA, MBA, senior analyst with New York City-based Prime Equity Research has initiated coverage on Bioheart with a 12-month stock target price and analyst's rating, in a report dated August 2, 2011.

unknown title 2011

Bioheart's president and CEO, Mike Tomas said, We were so excited to be one of the featured companies in this series and truly enjoyed working with Gary Cortell and his team.

unknown title 2011

On Wednesday September 14, 2011, 8:00 am EDT SUNRISE, Fla., Sept. 14, 2011 GLOBE NEWSWIRE -- Bioheart, Inc.

unknown title 2011

Bioheart has completed several preclinical studies demonstrating the safety and efficacy of this product including a study led by Keith March, MD, PhD, Director of the Vascular and Cardiac Center for Adult Stem Cell Therapy at the Indiana University.

unknown title 2011

Using the clinical data from a Phase I/II trial in Mexico and preclinical studies, Bioheart will apply to the FDA to begin a Phase I study in the US.

unknown title 2011

Bioheart is focused on completing the Phase II/III MARVEL study for chronic heart failure using MyoCell.

unknown title 2011